Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kathryn R Wagner

Showing results (1-10 of 120) with videos related to

Pageof 12
Sort By:
Current Opinion in Neurology|September 17, 2009
The state of the field: myologyKathryn R Wagner
Neurology|January 6, 2009
The need for biomarkers in amyotrophic lateral sclerosis drug developmentKathryn R Wagner
Continuum (Minneapolis, Minn.)|December 4, 2019
Facioscapulohumeral Muscular DystrophiesKathryn R Wagner
Neurologic Clinics|November 16, 2002
Genetic diseases of muscleKathryn R Wagner
Neurology|January 11, 2007
Enzyme replacement for infantile Pompe disease: the first step toward a cureKathryn R Wagner
Seminars in Cell & Developmental Biology|August 9, 2021
Progress in repairing muscleKathryn R Wagner
Current Opinion in Rheumatology|October 15, 2005
Muscle regeneration through myostatin inhibitionKathryn R Wagner
Current Opinion in Neurology|August 11, 2020
The elusive promise of myostatin inhibition for muscular dystrophyKathryn R Wagner
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|November 21, 2008
Approaching a new age in Duchenne muscular dystrophy treatmentKathryn R Wagner
The Journal of Clinical Investigation|May 16, 2022
Piezo1: opening the way to preventing muscle atrophyRavi Jagasia, Kathryn R Wagner
Pageof 12

Showing results (1-10 of 120) with videos related to

Sort By:
Pageof 12
Current Opinion in Neurology|September 17, 2009
The state of the field: myologyKathryn R Wagner
Neurology|January 6, 2009
The need for biomarkers in amyotrophic lateral sclerosis drug developmentKathryn R Wagner
Continuum (Minneapolis, Minn.)|December 4, 2019
Facioscapulohumeral Muscular DystrophiesKathryn R Wagner
Neurologic Clinics|November 16, 2002
Genetic diseases of muscleKathryn R Wagner
Neurology|January 11, 2007
Enzyme replacement for infantile Pompe disease: the first step toward a cureKathryn R Wagner
Seminars in Cell & Developmental Biology|August 9, 2021
Progress in repairing muscleKathryn R Wagner
Current Opinion in Rheumatology|October 15, 2005
Muscle regeneration through myostatin inhibitionKathryn R Wagner
Current Opinion in Neurology|August 11, 2020
The elusive promise of myostatin inhibition for muscular dystrophyKathryn R Wagner
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|November 21, 2008
Approaching a new age in Duchenne muscular dystrophy treatmentKathryn R Wagner
The Journal of Clinical Investigation|May 16, 2022
Piezo1: opening the way to preventing muscle atrophyRavi Jagasia, Kathryn R Wagner
Pageof 12